CLINICAL TRIALS

MOMENTUM STUDY: Efficacy and Safety of Pemvidutide in the Treatment of Obesity

STATUS: Ongoing

For more information

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Top line 48-wk results in Q4 2023.

IMPACT STUDY: Efficacy and Safety of Pemvidutide in Subjects with Nonalcoholic Steatohepatitis (NASH)

STATUS: Enrolling

For more information

The purpose of the study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Topline data in Q1 2025.

Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)

STATUS: Ongoing

For more information

A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB).

Top line data readout H1 2024.